News & Updates

Show Multimedia Only

Prostate volume predicts risk of grade progression in patients with prostate cancer

30 Sep 2026

Increased prostate volume in patients with low-grade prostate cancer on active surveillance appears to contribute to reduced risks of grade progression (GP) and receipt of definitive prostate cancer treatment, suggests a study.

30 Sep 2026

EV-induced cutaneous adverse events signal good prognosis in advanced urothelial cancer

29 Sep 2026

In patients with locally advanced or metastatic urothelial cancer, enfortumab vedotin (EV)-induced cutaneous adverse events (cAEs) are associated with improved survival outcomes, according to a retrospective study.

29 Sep 2026

SBRT shows slightly lower late GI and GU toxicities than conventional RT in prostate cancer

24 Sep 2026 by

Stereotactic body radiotherapy (SBRT) provides comparable 5-year biochemical progression-free survival (PFS) and is associated with slightly lower rates of gastrointestinal (GI) and genitourinary (GU) toxicities compared with conventional radiotherapy (RT) in Chinese patients with low- to intermediate-risk prostate cancer, according to a real-world study in Hong Kong.

24 Sep 2026

Increased saturated fat intake linked to high death rates among men with prostate cancer

20 Sep 2026 by

High intake of saturated and animal fats following a diagnosis of nonmetastatic prostate cancer is associated with increased mortality from cardiovascular disease and other cancers, according to a study. But the good news is that replacing saturated and animal fats with healthier plant-based fats may improve survival outcomes.

20 Sep 2026

Intensified triplet regimens may improve PFS in mHSPC

01 Sep 2026 by

First-line combination treatment with docetaxel plus androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) or poly(ADP-ribose) polymerase inhibitor (PARPi) plus ARPI plus ADT results in clinically relevant but not statistically significant improvements in progression-free survival (PFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), a study has found.

01 Sep 2026

Novel implantable device delivers durable efficacy, high patient satisfaction in women with UUI

20 Aug 2026 by

Revi, an implantable tibial neuromodulation system powered by a patient-controlled, external wearable ankle device, demonstrates durable efficacy, excellent safety profile, and high patient satisfaction in women with urgency urinary incontinence (UUI), a study has shown.

20 Aug 2026

Noninvasive UGN-102 therapy delivers durable response in recurrent LG-IR-NMIBC

05 Aug 2026 by

Patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) who achieved an initial complete response (CR) to UGN-102 treatment tend to remain event-free 24 months later, according to phase III ENVISION trial.

05 Aug 2026

Vitamin D plus enuresis alarm reduces wet nights, improves QoL in children with PMNE

04 Aug 2026 by

Combining high-dose vitamin D supplementation (VDS) with enuresis alarm (EA) therapy results in significant reductions in wet-night frequency and improves treatment response, satisfaction, and quality of life (QoL) relative to EA alone in children with primary monosymptomatic nocturnal enuresis (PMNE) and serum 25-hydroxyvitamin D (25[OH]D) levels below 30 ng/mL, a study has shown.

04 Aug 2026

RWE shows link between disturbed sleep, poor sperm quality

30 Jul 2026 by

A large real-world study presented at ESHRE 2026 shows an association between short sleep duration, sleep apnoea, and poor sperm quality.

30 Jul 2026

Reusable noninferior to single-use catheters for patients with urinary retention

13 Jul 2026

For patients with urinary retention requiring clean intermittent catheterization, the use of reusable catheters does not appear to increase the risk of urinary tract infection (UTI) and serious complications when compared with single-use catheters, according to a noninferiority randomized clinical trial.